✦ LIBER ✦

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

✍ Scribed by Peng, Bo ;Zhang, Jinnong ;Woods, Jamile S. ;Peng, Wei

Publisher: Higher Education Press and Springer
Year: 2009
Tongue: English
Weight: 296 KB
Volume: 3
Category: Article
ISSN: 1673-7342
DOI: 10.1007/s11684-009-0044-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Genomic signatures in non-small-cell lun

Genomic signatures in non-small-cell lung cancer: Targeting the targeted therapies

✍ Holly K. Dressman; Andrea Bild; Jennifer Garst; David Harpole; Anil Potti 📂 Article 📅 2006 🏛 Current Science Inc. 🌐 English ⚖ 204 KB

Molecular biological markers and microme

Molecular biological markers and micrometastasis in resected non-small-cell lung cancer

✍ Toshihiro Osaki; Tsunehiro Oyama; Masaaki Inoue; Chun-Dong Gu; Mantaro Kodate; M 📂 Article 📅 2001 🏛 Springer Japan 🌐 Japanese ⚖ 277 KB

How Affordable are Targeted Therapies in

How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?

✍ Linda E. Coate; Natasha B. Leighl 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 192 KB

Vaccine therapy in non—small-cell lung c

Vaccine therapy in non—small-cell lung cancer

✍ Carol Albright; Jennifer Garst 📂 Article 📅 2007 🏛 Current Science Inc. 🌐 English ⚖ 233 KB

Targeted therapies in advanced non-small

Targeted therapies in advanced non-small cell lung cancer: success or failure?

✍ E. Szutowicz; K. Konopa; J. Jassem 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 194 KB

Adjuvant therapy of non-small cell lung

Adjuvant therapy of non-small cell lung cancer

✍ E. Carmack Holmes 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 2 views

One hundred and forty thousand patients in the United States will develop lung cancer annually. About one half of these will have disease confined to the thorax with no clinical evidence of dissemination (Figure 1). A relatively high proportion of these patients will actually have disease that can b